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Abstract
Background: Epstein Barr virus (EBV) infects the majority of the human population, causing fatal diseases in a small
proportion in conjunction with environmental factors. Following primary infection, EBV remains latent in the memory B
cell population for life. Recurrent reactivation of the virus occurs, probably due to activation of the memory B-
lymphocytes, resulting in viral replication and re-infection of B-lymphocytes. Methylation of the viral DNA at CpG motifs
leads to silencing of viral gene expression during latency. Zta, the key viral protein that mediates the latency/reactivation
balance, interacts with methylated DNA. Zta is a transcription factor for both viral and host genes. A sub-set of its DNA
binding sites (ZREs) contains a CpG motif, which is recognised in its methylated form. Detailed analysis of the promoter of
the viral gene BRLF1 revealed that interaction with a methylated CpG ZRE (RpZRE3) is key to overturning the epigenetic
silencing of the gene.
Methodology and Principal Findings: Here we question whether we can use this information to identify which host genes
contain promoters with similar response elements. A computational search of human gene promoters identified 274 targets
containing the 7-nucleotide RpZRE3 core element. DNA binding analysis of Zta with 17 of these targets revealed that the
flanking context of the core element does not have a profound effect on the ability of Zta to interact with the methylated
sites. A second juxtaposed ZRE was observed for one promoter. Zta was able to interact with this site, although co-
occupancy with the RpZRE3 core element was not observed.
Conclusions/Significance: This research demonstrates 274 human promoters have the potential to be regulated by Zta to
overturn epigenetic silencing of gene expression during viral reactivation from latency.
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Introduction
Epstein Barr virus (EBV) infects and causes several diseases in
humans including Burkitt’s lymphoma, nasopharyngeal carcino-
ma, Hodgkin’s disease, post-transplant lymphoproliferative disor-
der and infectious mononucleosis (glandular fever) [1–4]. Like
other members of the gammaherpesviruses family, EBV infection
persists for life following primary infection. The virus is
maintained in a state of latency in memory B-lymphocytes and
occasional reactivation and replication is considered to maintain
the virus within individuals [5]. In EBV-induced lymphomas, EBV
is also present in a latent state. In cell lines derived from these
lymphomas, the viral genome is predominantly methylated [6–9].
The effect of silencing viral gene expression not only aids evasion
from the immune system [10], but also prevents the destruction of
tumour cells by viral replication. Indeed, reactivation of EBV from
latency has been proposed as a route to treat EBV-associated
lymphomas [11,12].
EBV latency is disrupted following physiological activation of B-
lymphocytes, through the expression of Zta (BZLF1, ZEBRA,
EB1, Z) [13–15]. Zta is a sequence-specific DNA-binding protein,
which resembles the bZIP family of transcription factors and plays
a critical role in the reactivation of viral gene expression and
replication of the genome. Through direct interaction with Zta
response elements (ZREs) in promoters, Zta regulates the
expression of viral and cellular genes. Many host and viral
promoters that have been evaluated to date contain ZREs within
the proximal five hundred nucleotides of 59 sequence. Thus far,
eight have experimentally verified binding sites for Zta in their
proximal promoter regions:
BSLF2+BMLF1 [16,17]; BRLF1 [18]; BZLF1 [17,19,20]; the
joint promoter for BHLF1 and BHRF1 [19]; the lytic EBNA1
promoter Fp [21]; BRRF1 [22]; and BMRF1 [23]. Furthermore, 6
host genes are directly regulated by Zta through ZREs in their
promoters DHRS9 [24]; EGR1 [25,26]; CIITA [27]; IL-8 [28]; IL-
10 [29]; and IL-13 [30]. Zta interacts with a diverse range of ZREs
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[31] and multiple sites exist in some Zta-responsive promoters,
sometimes in close proximity. One example is the viral promoter
for the BZLF1 gene, Zp, which contains the two functional ZIIIA
and ZIIIB ZREs within a total span of 20 nucleotides [17,19,20].
Zta has the unusual feature of interacting with a sub-set of ZREs
that contain a methylated CpG motif [32]. In some cases Zta is
able to interact with the non-methylated ZRE, while for other
ZREs the interaction with Zta is dependent on methylation
[22,26,32–34]. This has led to the classification of ZREs into three
classes: class I ZREs do not contain a CpG motif; class II ZREs
contain a CpG motif that is recognized in both the methylated and
non-methylated states; and class III ZREs contain a CpG motif
but are only recognized when methylated [35]. The ability of Zta
to interact with methylated CpG-containing ZREs allows Zta to
activate gene expression in the latent viral genome despite the
repressive methylation status and thus overturn the epigenetic
silencing of the viral genome [22,32–35].
To date, three genes with CpG-containing ZREs have been
studied: EBV BRLF1, EBV BRRF1 and human EGR1 [22,26,32–35].
Of these, investigation of the regulation of the EBV gene BRLF1
provided compelling evidence that the interaction of Zta with a
methylated ZREwas instrumental in reactivating EBV into lytic cycle
in B-lymphocytes [32–35]. The viral BRLF1 gene includes three
ZREs in the promoter proximal region [18,32]. Two of the ZREs
contain CpG motifs; RpZRE2, is a class II ZRE and the other,
RpZRE3 is a class III ZRE [35]. The ability of a single point-
mutation in Zta to differentiate between the interaction of Zta with
methylated and non-methylated RpZRE3 allowed the relevance of
the interaction of Zta with this promoter to be established [34,36,37].
The viral BRRF1 gene contains two CpG-containing ZREs, which
Zta only interacts with in their methylated states [22]. The presence
of a CpG-containing ZRE in the promoter of the human EGR1 gene,
which is recognized by Zta in its methylated form, suggests that EBV
may overturn epigenetic silencing of host genes in order to modulate
the host cell environment [26].
The RpZRE3 core element (TCGCGAA), which was clearly
shown to be required for overturning epigenetic silencing of
BRLF1 in B-lymphocytes [34,36,37], was chosen to identify all
human genes that contain an exact match to this CpG-containing
ZRE within the 2500 to +1 region of the promoter and evaluate
whether they are recognised by Zta in their natural context.
Materials and Methods
Identification of Human Promoters Containing RpZRE3-
Core Elements: Initial Sampling
Promoter regions (defined as 2500 to +1 base pairs from the
transcription start site) of a sample of human protein-coding genes
in Ensembl (49) [38] were extracted using the Biomart data
management system [39]. The sample represented 40% of the
human genome. A search was made for all occurrences of an exact
(forwards and reverse) match to identify those promoters with the
TCGCGAA RpZRE3 core element.
Identification of Human Promoters Containing RpZRE3-
Core Elements: Whole Genome Scanning
An identical screen was undertaken on the entire human
genome from Ensembl (50) [40], resulting in the identification of
274 promoters which were designated the RpZRE3-promoter-
274 data-set. The 7 nucleotides of the RpZRE3 core element,
along with 10 flanking nucleotides on each side, were extracted
from each of the 5 genes from the initial sampling. The
Transcription Factor Binding Site (TFBS) Perl modules [41]
were used to create a Position Weight Matrix (PWM) based on
the entire length of these 27-nucleotide sequences. TFBS Perl
modules were also used to search the promoter regions (2500 to
+1) of all human protein coding genes in Ensembl 50 [40] which
were extracted using Biomart [39]. Those promoters that
matched the PWM with a threshold value .80% and contained
an exact match to the RpZRE3-core element were additionally
filtered using 2 criteria (a) the presence of CpG islands and (b)
function (based on the over-representation of Gene Ontology
(GO) terms [42]). The location of CpG islands were predicted
using the EMBOSS program CpGPlot [43] with default options.
Only genes with a CpG island present in the promoter were
retained. The GO term annotations for molecular function and
biological processes were extracted from Ensembl for each gene
[40]. The number of genes in the RpZRE3 promoter dataset with
each GO term annotation was compared with the total number
of genes in Ensembl with the same GO term. The GO terms that
occurred with a significantly higher frequency (p,0.05) in the
RpZRE3 dataset, compared to entire genome, were defined as
over-represented.
DNA Binding Analysis by EMSA on RpZRE3 Containing
Promoters
Double stranded labelled DNA probes were made by labelling
6 pmol of oligonucleotide (27 nt long) at the 59 end with
[c-32P]ATP (30 mCi) using polynucleotide kinase (Roche).
12 pmol of the complementary oligonucleotide strand was added
and incubated with the labelled single strand at 95uC for 2
minutes, 65uC for 10 minutes, and 37uC for 30 minutes to anneal
the strands. The concentration of the probe was 33.3 nM. The
oligonucleotides comprised the core 7-mer sequence surrounded
by 20 nucleotides corresponding to the cognate flanking sequence
for each promoter and were synthesised. Where indicated in the
figure, the central CpG motif was methylated on both cytosines
during synthesis (Sigma).
Zta protein was in vitro translated using wheatgerm extract
(Promega). This was incubated with the labelled probe (at a final
probe concentration of 3.3 nM) for 30 minutes at room
temperature, before the sample was fractionated on an 8% native
polyacrylamide gel at 100 volts for 1 hour. Following detection of
the radio labelled DNA using a Storm phosphorimager, the
relative signals were quantitated using ImageQuant software (GE
Healthcare, UK).
Competition EMSAs were carried out with a 100X excess of a
double stranded non-labelled oligonucleotide in addition to the
standard EMSA reaction. Equal quantities of each of the
complementary oligonucleotides were annealed in the same
manner as the labelled probes and diluted to yield a solution
concentration of 3.33 mM. This was added to the EMSA reaction
at a final concentration of 333 nM (i.e. 100X excess).
Oligonucleotides
The oligonculeotides used were double strand versions of the
following sequences (59-39):
XPC GGTGCGTCACTCGCGAAGTGGAATTTG
ZC3H8 GCTTCCCGGCTCGCGAAAGGGAGGACC
HDAC2 TCCCCCACTGTCGCGAAGCTCCCGCCC
MNT CCGCGGCGTCTCGCGAAGGGAGGGGCG
Cyclin L2 GGGCGGCTCCTCGCGAAGCTCCACGGC
RpZRE3 GTTTATAGCATCGCGAATTTTGAGTGC
CAPN2 CCGGGGAGGCTCGCGAATCGCGGTCCA
CDO1 CGTCCCAGCGTCGCGAACCACAGCGGC
FALZ GGCGCGCAGCTCGCGAAATGCCCGGCG
KIF1B GCTTCGGCCCTCGCGAAACTCCGCCCG
LLGL1 TCGGCCGGGCTCGCGAAGGGACGCCCG
EBV Epigenetic Reprogramming
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LMO4 GGATCCCGGGTCGCGAAGGGCAGCCCA
MBD4 CCTCCTGCTCTTCGCGAACCGCCCCGC
PLEKHJ1 AGCCGCTCCCTCGCGAAAGTTGGCCCC
PRKD1 CTTCCTGGGGTCGCGAACTTCCCGGGC
SEC14L CGCCCGCTACTCGCGAAGCCCAGCCCG
TADA3L GCTGCGCTTCTCGCGAAAGGGCAGGCA
TOP2B CCGCGCCCCATCGCGAAGATCCGGAGC
XPCLMNTR GGTGCGTCACTCGCGAAGGGAGGGGCG
MNTLXPCR CCGCGGCGTCTCGCGAAGTGGAATTTG
XPC Mcore GGTGCGTCACCCCCTTAGTGGAATTTG
XPCLM3Mcore GGTCCGCCTCCCCCTTAGTGGAATTTG
AP1 mut GATCCACCCCTTAGAGGAAAACATACG
Prediction of Transcription Factor Binding Sites Using
Promo
The transcription factor binding site prediction program
PROMO [44] was used with the default setting of 15%
dissimilarity value, to identify potential bZIP transcription factor
binding sites within the XPC oligonucleotide.
Results
Identification of Human Promoters Containing the
RpZRE3-Core Element: Initial Sampling
The initial search for RpZRE3-core elements in a sample of
human promoters revealed 67 genes with an RpZRE3-core
element. 5 of these that are involved in gene regulation were
selected for DNA binding analysis. These 5 genes were ZC3H8
(ENSG00000144161), HDAC2 (ENSG00000196591), XPC
(ENSG00000154767), MNT (ENSG00000070444) and CyclinL2
(ENSG00000116148) and together with the RpZRE3 element
from the viral BRLF1 promoter (Rp), formed the RpZRE3-
promoter-6 data-set.
DNA-binding assays were undertaken with the methylated
forms of each of the 5 human promoters using 27mer double
strand oligonucleotides encompassing the 7-nucleotide core
element and 10-nucleotide flanking region on each side together
with RpZRE3 from Rp. Electrophoretic mobility shift assays
(EMSA) were undertaken with in vitro translated Zta protein. Zta
protein/DNA complexes formed readily with the oligonucleotides
from all six promoters (Figure 1). The specificity of the assay is
shown by the lack of complex formation with control protein. In
addition, we undertook competition experiments with an excess of
unlabelled oligonucleotides and included a version with a mutant
ZRE to further probe the specificity of the interaction. This
confirms that Zta interacts with all six RpZRE3 core elements
specifically.
Identification of Human Promoters Containing RpZRE3-
Core Elements: Whole Genome Scanning
The complete human genome was scanned for additional
RpZRE3-core elements. This resulted in a data-set of 274 genes,
denoted the RpZRE3-promoter-274 data-set (see Table S1). To
assess whether there was an influence of flanking sequence on the
interaction of Zta with these ZREs we undertook a systematic
filtering process. The RpZRE3-promoter-274 dataset was first
filtered by a Position Weight Matrix (PWM), which was generated
from the RpZRE3-promoter-6 data-set. Matches were further
filtered for genes with at least one CpG island in the promoter and
an over-represented GO term. This resulted in 12 previously
unidentified promoters and a further one that had been identified
in the initial screen (Figure 2). Together with the promoters from
the initial screen and the viral BRLF1 promoter (RpZRE3-
promoter-6 data-set), these form the RpZRE3-promoter-18 data-
set.
Oligonucleotides were designed using the same principles with
10 nucleotides of flanking sequence on each side of the RpZRE3-
core element, and the ability of Zta to interact with each site in its
methylated form was assessed. The EMSA analysis revealed that
all twelve of the newly identified methylated promoters were
recognised by Zta (Figure 3).
This analysis demonstrated that for the RpZRE3-promoter-18
data-set, the flanking sequence surrounding the methylated core 7-
mer element did not have a profound effect on the ability of Zta to
interact with promoters and therefore the core element was
sufficient to facilitate binding. This was illustrated by the
generation of a PWM using sequence from the RpZRE3-
promoter-18 data-set (Figure 4), which revealed negligible
sequence conservation outside of the core element.
Recognition of the Non-Methylated Promoters
Zta is able to recognise many response elements which do not
contain a CpG motif and therefore do not have a methylated core
element (Class I ZREs) [15,35]. In addition, Zta recognises one
CpG containing ZRE, RpZRE2, even in the absence of
methylation (Class II ZREs) [33]. The ability of Zta to recognise
the promoters in their non-methylated forms may impact on the
ability of EBV to alter their gene expression, so we investigated the
classification of ZRE for each of the 17 human promoters.
A series of DNA binding experiments with the oligonucleotides
representing the human promoters in the RpZRE3-promoter-18
data-set, were undertaken comparing non-methylated with
methylated RpZRE3-core elements. The interaction of Zta with
the sites was quantitative, as demonstrated by the reduction in
complex formation as the Zta protein concentration was titrated
on each of the methylated promoters (Figure 5). All bar one
display negligible binding to the non-methylated oligonucleotides
(at least 10-fold lower than to the methylated sites) and can
therefore be classified as class III ZREs.
Zta displayed a reproducible interaction with the non-
methylated XPC oligonucleotide; the interaction reached 50% of
the binding observed with the methylated oligonucleotide
(Figure 5). This raises the possibility that the XPC core RpZRE3
element is influenced by the flanking sequence to behave as a class
II ZRE.
Additional ZRE Juxtaposed with an RpZRE3-Core Element
in Flanking Region
To identify whether sequences conferring methylation indepen-
dent recognition was confined to a specific flank of XPC, a series
of mutant oligonucleotide probes that exchanged flanking
sequences between XPC and a class III site (MNT), that is not
recognised when non-methylated, were designed. Analysis of the
interaction with Zta by EMSA revealed that the ability to confer
Zta binding resided within the 59 sequence of XPC; the hybrid
XPCLMNTR was able to bind but MNTLXPCR was not
(Figure 6). This suggested that the 59 XPC flanking sequence of the
RpZRE3 element influenced binding. However, it was surprising
to discover that mutation of the RpZRE3 element within XPC did
not prevent interaction with Zta (Figure 6).
A further explanation for the interaction of Zta with the non-
methylated XPC promoter is that an obscure ZRE is present in
the 59 flank. To address this further we attempted to identify
putative ZREs in the XPC promoter using the transcription factor
binding site prediction program PROMO [44,45]. Although this
program contains a PWM for Zta binding sites, none were
predicted in this sequence. However, PROMO predicted the
EBV Epigenetic Reprogramming
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Figure 1. Interaction of Zta with methylated RpZRE3 core element from 5 human promoters. (a) The nucleotide sequence of one strand
of each oligonucleotide spanning the indicated ZREs is shown, with the conserved RpZRE3 core element (TCGCGAA) aligned. Double strand versions
of these sequences were used as probes in EMSA, with the 2 cytosines within the CpG core motif methylated. The RpZRE3 from EBV BRLF1 promoter
is included. (b) DNA binding between in vitro translated Zta with each probe was undertaken by EMSA. The ability of Zta (Z) to interact with the
probe was compared with an unprogrammed translation lysate (C) as a negative control. The complex was separated on an 8% gel by electrophoresis
and visualised by phosphoimaging. The excess probe can be seen at the bottom of the gel. The probe used in each experiment is indicated below
the gel. (c) Competition of each ZRE sequence (at 100X excess) against labelled RpZRE3 was determined by competition EMSAs. Data from at least 2
experiments was taken to calculate competition i.e. the percentage of labelled probe displaced by unlabelled competitor. Methylated ZREs were used
for both probe and competition. AP1 mut, an oligonucleotide previously shown not to interact with Zta [36], was used as a negative control to define
the level of non-specific binding. Error bars indicate standard error.
doi:10.1371/journal.pone.0009443.g001
EBV Epigenetic Reprogramming
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Figure 2. Identification of human promoters containing RpZRE3 core elements in the human genome. (a) The bioinformatics analysis
undertaken for the genome wide scan is represented as a flow diagram. Genetic input or output is represented by ovals, and filters by trapeziums. (b)
A Position Weight Matrix (PWM) was created using the aligned sequences of the RpZRE3-promoter-6 data-set. These sequences are shown in Fig. 1(a).
This was used to filter the genomic data from the human promoter sequences (2500 to +1). (c) Overrepresented GO terms found for the 274 genes
were identified. (d) The 13 genes identified as candidate genes, 12 previously unknown genes and 1 from the initial screen, and their associated
Ensembl accession codes.
doi:10.1371/journal.pone.0009443.g002
EBV Epigenetic Reprogramming
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presence of AP1, c-fos and c-jun binding sites within the 59 flank of
XPC (59TGCGTCA) (Figure 7). c-fos and c-jun proteins are both
members of the bZIP transcription factor family; they form AP1
DNA binding activity as either homodimers or heterodimers. It is
relevant that fos/jun dimers share some DNA recognition motifs
with Zta [15–17,31,46–49]. This led to the hypothesis that the
predicted AP1 site in the 59 flanking sequence is an additional
ZRE that is responsible for binding to the non-methylated XPC
oligonucleotide. To test the hypothesis, further mutations were
introduced into the 59 XPC flanking sequence in the predicted
AP1 site (59TCCGCCT). The ability of Zta to interact with the
double AP1/core mutant site (XPCLM3Mcore) was compared
with the core-only mutant. Dual mutation of the predicted AP1
site and the core abrogated the ability of Zta to interact with the
XPC oligonucleotide, demonstrating that binding of Zta to the
non-methylated XPC site resided with this AP1 site (Figure 7).
This analysis showed that the RpZRE3 core element is not
recognised in its non-methylated state in the context of any of the
viral or cellular promoters in the RpZRE3-promoter-18 data-set,
and that this ZRE is specifically recognised when methylated.
Discussion
A computational search revealed a set of 274 human genes with
cellular promoters containing the 7-mer RpZRE3 core element.
Flanking sequence can influence the interaction of some
transcription factors with DNA, for example, the interaction of
the E2F family with DNA is influenced by a region of at least 8
nucleotides 59 and 11 nucleotides 39 to the central nucleotide [50].
Before assigning all 274 genes as candidates for regulation by Zta,
it was important to assess whether the cognate flanking sequence
had a profound effect on binding by Zta. Consideration of the
sequences represented in the flanking sequence of this set of genes
revealed it to be diverse; all four nucleotides were represented in
55% of positions and three of the four nucleotides were
represented at the remaining positions. Indeed, the immediate
flank of the RpZRE3 core element, consisting of four nucleotides
both 59 and 39, had 100% representation of all four nucleotides. It
can therefore be concluded that the flanking sequence does not
prevent binding to the methylated RpZRE3 core, and a PWM
generated from the RpZRE3-promoter-18 data-set showed little
conservation outside the core motif. In contrast, the interaction
with the non-methylated core element initially appeared to be
influenced by flanking sequence in only 1 of the 18 promoters.
However, further analysis revealed this to be due to the presence of
a second ZRE in the flanking sequence.
These results show that the approach of undertaking a
computational pattern match search for the 7-mer RpZRE3 core
element is a fast and reliable method to identify promoters
containing ZREs that are recognized by Zta only when they are
methylated (class III ZREs).
The identification of two adjacent juxtaposed ZREs in the XPC
promoter presents an interesting problem; can both sites be
occupied at once? The natural juxtaposition of ZREs has been
previously described for a viral promoter; BZLF1 and a cellular
promoter EGR1. In the BZLF1 promoter, the elements are situated
with 12 base pairs between the central nucleotides; both can be
occupied simultaneously and both are functionally relevant
[17,19–20]. For the EGR1 promoter, the elements are immediately
adjacent with just 8 nucleotides between the central nucleotides
[25,26]. There is no evidence for simultaneous occupation by Zta
and only one element appears to be functional in vivo [26]. The
arrangement of the XPC promoter places the elements 8
nucleotides apart, identical to EGR1, and there is no evidence
from the DNA-binding experiments for simultaneous occupation
of the sites. As one ZRE is recognised in a methylation-dependent
manner and the other is recognised when non-methylated, it is
possible that the arrangement may provide a fail-safe mechanism
to ensure that the gene is regulated in both its methylated and non-
methylated states.
Figure 3. Interaction of Zta with methylated RpZRE3s found in
human promoters. EMSA analysis with in vitro translated Zta protein
(Z) or an unprogrammed translation lysate (C) with the probes indicated
to the right of each gel was carried out as described in Fig. 1.
doi:10.1371/journal.pone.0009443.g003
Figure 4. Analysis of the RpZRE3 core element flanking sequence. (a) A Position Weight Matrix (PWM), created using the probe sequences of
the dataset RpZRE3-promoter-18.
doi:10.1371/journal.pone.0009443.g004
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The simple computational approach taken to identify the
location of this methylation-dependent and novel DNA-binding
motif in human gene promoters identified 274 genes potentially
regulated by overcoming epigenetic silencing during the viral
replicative cycle. Given the known functions of Zta in reprogram-
ming viral gene expression, disrupting cell cycle control and
replicating viral DNA, it is interesting to note that the Gene
Ontology terms that are over-represented in the RpZRE3-
promoter-274 gene-set are largely involved in transcription,
chromatin re-modelling and mitosis. This strongly suggests that
Zta may activate this set of cellular genes in order to accomplish
these functions. Testing whether these genes are activated during
latency disruption in memory B-lymphocytes in vivo is technically
challenging given both the scarcity of memory B-lymphocytes in
peripheral circulation and the infrequency of latency disruption in
vivo.
The co-location of the RpZRE3 core element in 274 human
promoters is unlikely to have been driven by an evolutionary
advantage to the virus, but may reflect the involvement of a
cellular transcription factor interacting with the same element.
This would suggest that this set of genes share a common mode of
regulation during human development or differentiation. Further
Figure 5. Comparison of Zta interaction with non-methylated and methylated RpZRE3s from human promoters. DNA binding analysis
of in vitro translated Zta protein (Z) or an unprogrammed translation lysate (C) with both non-methylated and methylated versions of the probes
indicated to the right of each gel was carried out by EMSA as described in Fig. 1. A titration of Zta protein (1:2, 1:4, 1:8) was used to compare non-
methylated binding to that of the methylated equivalent. Quantitation of the complexes formed between Zta and the non-methylated and
methylated probes, from at least 2 experiments, is represented as a histogram to the right of the corresponding gel. Complex formation is shown
relative to the maximum binding for each probe. Error bars indicate standard error.
doi:10.1371/journal.pone.0009443.g005
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more, it will be interesting to question whether co-occurrence of
the RpZRE3-core element with other transcription factor binding
sites forming a co-operative cis-regulator module which may
illuminate the regulation of these host and viral genes.
Supporting Information
Table S1 RpZRE3-promoter-274 data-set: A table of genes
which contain a RpZRE3 core element in the 500 bp promoter
region.
Found at: doi:10.1371/journal.pone.0009443.s001 (0.05 MB
XLS)
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